Delirium Clinical Trial
Official title:
Safety, Tolerability, and Early Efficacy of Immersive Virtual Reality for Early Neurocognitive Stimulation in the Intensive Care Unit.
New or worsening cognitive impairment occurs in up to 58% of survivors of critical illnesses
and are long-lasting with significant disability and socioeconomic cost. There are currently
no known interventions that reduce the incidence of cognitive impairment after critical
illnesses. Immersive Virtual Reality (IVR) is the use of technology to create a perception of
presence in a three-dimensional, computer-generated interactive simulated environment. Prior
clinical studies have demonstrated potential efficacy in rehabilitation of severe traumatic
brain injury.
The investigators propose a preliminary study for the evaluation of safety, tolerability, and
early efficacy of immersive virtual reality for early neurocognitive stimulation in
critically-ill, mechanically ventilated patients. The investigators hypothesize that the use
of IVR technology for early neurocognitive simulation is safe and tolerable in these
patients. This study will also evaluate whether early application of IVR in critically ill,
mechanically ventilated subjects, can provide neurocognitive stimulation.
30 patients admitted to the intensive care unit for acute respiratory failure or septic shock
will be evaluated for recruitment. 10 patients will be in the control group and 20 patients
would have 2 sessions of IVR planned daily for a maximum of 3 days. Assessment of safety will
involve monitoring for physiological derangements in heart rate, respiratory rate, pulse
oximetry and blood pressure during the IVR session. Assessment of tolerability will involve
monitoring for increased agitation. Assessment of early efficacy will involve evaluation of
visual attention during the IVR session. 5-channel electroencephalogram would aim to detect
objective changes in visual event-related potentials and the IVR headgear will incorporate
eye-tracking technology.
To conclude, should IVR be feasible and safe, future interventional studies may be planned to
investigate its impact on reduction in the use of sedatives, analgesia, delirium incidence
and severity of cognitive impairment associated with critical illness.
Advancements in the last 2 decades in the field of critical care medicine has led to an
improvement in mortality of critically ill patients. This has led to interest in the
long-term functional disabilities that the survivors suffer. The risks of developing
cognitive dysfunction after critical illness has been associated with older age, longer
duration of critical illness, hyperglycaemia, prolonged use of sedatives and analgesia, as
well as delirium. The BRAIN-ICU study reported that in adults with respiratory failure and
shock, the incidence of cognitive impairment at 1 year was 34% for 1.5 SD below population
mean (similar to moderate traumatic brain injury) and 24% for 2.5 SD below population mean
(similar to mild Alzheimer's disease). Some proposed mechanisms include cerebral hypoxia
secondary to respiratory failure, cerebral inflammation and neuronal apoptosis related to
sepsis, and prolonged disruption of sleep cycles. Neuronal imaging such as diffusion-tensor
MRI during critical illness show diffuse hyperintense white matter changes and subsequent
distant imaging studies show generalised cerebral atrophy.
Critical care societies have endorsed the use of care bundles for pain, agitation and
delirium management. Few specialised centres with dedicated survivor clinics evaluate
functional impairment via diagnostic investigations, physical, neurological examinations and
psychological assessments, to provide personalised rehabilitation. While these initiatives
have been shown to improve patient satisfaction, quality of transitional care and reduction
of inappropriate emergency room visits, there are no definitive interventions that have
improved cognitive outcomes.
Psychiatric co-morbidities of anxiety, depression and post-traumatic stress disorder(PTSD)
have been shown to be associated with delirium and cognitive impairment after critical
illness. Survivor accounts revealed a mixture of delusional and factual memories resulting in
the distortion of experiences. Intensive care diaries involve the recording of significant
daily events and is an attempt at systematic reconstruction of memories by medical staff,
family and friends. This has been shown to reduce the incidence of PTSD after critical
illness. It raises the possibility that incidence of cognitive impairment, too, may be
reduced with non-pharmacological methods.
An intensive care admission involves the immersion of a patient in a foreign environment that
is dominated by machines, the use of esoteric language by medical staff and persistent sleep
disruption that combines deprivation of meaningful sensory stimulation with noxious sensory
overload of alarms and lights. There is an unmet need for the provision of a calm, familiar
environment, and deliberate neurocognitive simulation with the intention of allowing
processes of thought, reasoning, memory and imagination to occur as they do in everyday life.
Allowing these cognitive processes to occur may reduce the use of sedatives, delirium
occurrence, and possibly cognitive impairment. Cognitive impairment after critical illness is
known to decrease the rehabilitation potential of survivors, increase caregiver burden and is
associated with higher utilisation of long-term healthcare resources. There is a need for
interventional clinical studies that address prolonged cognitive impairment after critical
illnesses.
The overall aim of the study is to improve clinical outcomes in critically ill and
mechanically ventilated patients.
The primary hypothesis is that the use of an immersive virtual reality headset for early
neurocognitive stimulation in critically ill, mechanically ventilated patients is safe and
well tolerated (i.e., does not result in significantly increased agitation).
The primary outcome of the study would be the composite endpoint of both safety and
tolerability. The immersive VA is considered as safe and tolerable if the patient does not
experience any safety or tolerability events. In both arms, subjects who complete of 4 out of
4 to 6 planned sessions would be considered as having met criteria for both safety and
tolerability. If 3 or less sessions were initiated, completion of 2 or more sessions would be
considered for having met criteria for both safety and tolerability. The IVR intervention
would be considered safe and tolerable if the difference in composite endpoint in the
intervention arm is not 20% more than the control arm.
Demonstration of safety, defined as the non-occurrence of significant physiological events
that require early termination of the IVR session. The use of an iVR is safe and does not
cause physiological changes that require the termination of more than 2 out of 6 planned
interventions.
Demonstration of tolerability, defined as: the occurrence of the event that the Richmond
Agitation-Sedation Score (RASS) greater than or equal to +2 during the use of the immersive
virtual reality headset and for the immediate 15 minutes after completion. The RASS score,
ranging from -5 to +4, is a validated scoring system used by clinical staff to evaluate the
degree of sedation and agitation of mechanically ventilated patients. A score of +2 reflects
an agitated state that is characterised by frequent non-purposeful movement or presence of
patient-ventilator dys-synchrony. Each subject has 6 planned interventions, completion of 4
out of 6 interventions would be considered demonstration of tolerability.
There are 2 secondary aims in this study to demonstrate early efficacy in terms of
neurocognitive stimulation. One would be comparing change in the EEG data after the immersive
VR sessions from the baseline, that may indicate visual attention. The hypothesis is that
visual attention during the intervention can be demonstrated with EEG waveforms. The other
secondary aim will be evaluation of the eye-tracking software as a potential tool for
meaningful interaction.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04551508 -
Delirium Screening 3 Methods Study
|
||
Recruiting |
NCT05891873 -
Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Recruiting |
NCT06194474 -
Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
|
||
Completed |
NCT03095417 -
Improving the Recovery and Outcome Every Day After the ICU
|
N/A | |
Completed |
NCT05395559 -
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
|
||
Terminated |
NCT03337282 -
Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
|
||
Not yet recruiting |
NCT04846023 -
Pediatric Delirium Screening in the PICU Via EEG
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Withdrawn |
NCT02673450 -
PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
|
||
Recruiting |
NCT03256500 -
Transcranial Direct Current Stimulation for the Treatment of Delirium
|
N/A | |
Not yet recruiting |
NCT02892968 -
ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients
|
N/A | |
Completed |
NCT02890927 -
Geriatric-CO-mAnagement for Cardiology Patients in the Hospital
|
N/A | |
Recruiting |
NCT03165539 -
Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
|
||
Completed |
NCT02518646 -
DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models
|
N/A | |
Completed |
NCT02554253 -
The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction
|
Phase 2 | |
Recruiting |
NCT02305589 -
The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium
|
N/A | |
Completed |
NCT02628925 -
Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale
|
N/A |